Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 5:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 109 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: FAP Clear all
Active, not recruiting Phase 1 Interventional

A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors

NCT06544655
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
BMS-986484, Nivolumab, Oxaliplatin, Capecitabine, Fluorouracil, Calcium folinate
Drug · Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
5
States / cities
Tucson, Arizona • Los Angeles, California • Grand Rapids, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 5, 2026, 5:29 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate Safety and Therapeutic Activity of RO6874281 in Combination with Pembrolizumab, in Participants with Advanced or Metastatic Melanoma

NCT03875079
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
RO6874281, Pembrolizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
4
States / cities
New Haven, Connecticut • Iowa City, Iowa • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 2, 2024 · Synced Sep 5, 2026, 5:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate How Multiple Oral Doses of AZD2389 Affect the Pharmacokinetics of Midazolam, Caffeine, and Bupropion in Healthy Participants

NCT06973005
View directory record Official record
Conditions
Advanced Chronic Liver Disease, Healthy Participants
Interventions
AZD2389, Midazolam, Caffeine, Bupropion
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Sep 5, 2026, 5:29 PM EDT
Terminated Phase 1 Interventional

FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)

NCT05432193
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Esophageal Cancer, Melanoma (Skin), Soft Tissue Sarcoma, Head and Neck Squamous Cell Carcinoma, Cholangiocarcinoma
Interventions
[Ga-68]-PNT6555, [Lu-177]-PNT6555
Drug
Lead sponsor
POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Sep 5, 2026, 5:29 PM EDT
Not listed No phase listed Observational

Exercise Effect on Transthyretin Stability

NCT04986826
View directory record Official record
Conditions
Amyloidosis Transthyretin, Athlete Heart
Interventions
Not listed
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Timeline
2021
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 2, 2021 · Synced Sep 5, 2026, 5:29 PM EDT
Terminated No phase listed Observational

Ileal Pouch-Anal Anastomosis Registry

NCT01026480
View directory record Official record
Conditions
Ileal Pouch-Anal Anastomosis
Interventions
Not listed
Lead sponsor
Boston Medical Center
Other
Eligibility
Not listed
Enrollment
936 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 16, 2017 · Synced Sep 5, 2026, 5:29 PM EDT
Completed No phase listed Observational

Carpal Tunnel Syndrome and Amyloid Cardiomyopathy

NCT02792790
View directory record Official record
Conditions
Amyloidosis, Cardiomyopathy, Transthyretin Amyloidosis, Senile Systemic Amyloidosis, Carpal Tunnel Syndrome
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
50 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 21, 2021 · Synced Sep 5, 2026, 5:29 PM EDT
Active, not recruiting Phase 3 Interventional Results available

HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

NCT04153149
View directory record Official record
Conditions
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Interventions
Vutrisiran, Sterile Normal Saline (0.9% NaCl)
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
655 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
17
States / cities
La Mesa, California • Los Angeles, California • Stanford, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced Sep 5, 2026, 5:29 PM EDT
Completed Phase 1 Interventional Results available

Lyophilized Black Raspberries in Adults With Familial Adenomatous Polyposis (FAP)

NCT00770991
View directory record Official record
Conditions
Familial Adenomatous Polyposis
Interventions
Black raspberry (BRB) Slurry, Black Raspberry (BRB) Suppositories, Black Raspberry (BRB) Placebo Slurry
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 14, 2016 · Synced Sep 5, 2026, 5:29 PM EDT
Completed Not applicable Interventional

Managing Childhood Abdominal Pain

NCT01620606
View directory record Official record
Conditions
Pediatric Abdominal Pain
Interventions
Cognitive Behavioral Therapy & Social Learning, Education and Support
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
7 Years to 12 Years
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
3
States / cities
Chapel Hill, North Carolina • Seattle, Washington • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Apr 26, 2021 · Synced Sep 5, 2026, 5:29 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy

NCT03860935
View directory record Official record
Conditions
Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis, Cardiomyopathies, Heart Diseases
Interventions
acoramidis, Placebo Oral Tablet
Drug
Lead sponsor
Eidos Therapeutics, a BridgeBio company
Industry
Eligibility
18 Years to 90 Years
Enrollment
632 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
40
States / cities
Los Angeles, California • Santa Monica, California • Aurora, Colorado + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Sep 5, 2026, 5:29 PM EDT
Completed No phase listed Observational

Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Transthyretin Amyloid Cardiomyopathy

NCT06393465
View directory record Official record
Conditions
Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
Interventions
Tafamidis
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 5, 2026, 5:29 PM EDT
Completed No phase listed Observational

Hereditary Colorectal and Associated Tumor Registry Study

NCT00633607
View directory record Official record
Conditions
Lynch Syndrome, FAP, Hereditary Diffuse Gastric Cancer, Juvenile Polyposis Syndrome, Peutz-Jeghers Syndrome
Interventions
Research Registry
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
8 Years to 100 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 18, 2018 · Synced Sep 5, 2026, 5:29 PM EDT
Recruiting Phase 3 Interventional

Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis

NCT06950385
View directory record Official record
Conditions
Familial Adenomatous Polyposis (FAP)
Interventions
eRapa (encapsulated rapamycin), Placebo
Drug
Lead sponsor
Rapamycin Holdings Inc.
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
18
States / cities
Arcadia, California • New Haven, Connecticut • Washington D.C., District of Columbia + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 5, 2026, 5:29 PM EDT
Terminated Not applicable Interventional Results available

An Evaluation of SprayShield in Reducing Post-Operative Adhesion Formation Following Major Open Abdominal Surgery

NCT01002287
View directory record Official record
Conditions
Ulcerative Colitis, Familial Polyposis
Interventions
SprayShield Adhesion Barrier System, Good Surgical Technique Alone
Device · Procedure
Lead sponsor
Integra LifeSciences Corporation
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Bedford, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 19, 2014 · Synced Sep 5, 2026, 5:29 PM EDT
Recruiting Phase 3 Interventional

MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

NCT06128629
View directory record Official record
Conditions
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Interventions
NTLA-2001, Placebo
Biological · Drug
Lead sponsor
Intellia Therapeutics
Industry
Eligibility
18 Years to 90 Years
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
38
States / cities
Tucson, Arizona • Los Angeles, California • Palo Alto, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 5, 2026, 5:29 PM EDT
Completed Phase 3 Interventional Results available

HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)

NCT03759379
View directory record Official record
Conditions
Amyloidosis, Hereditary, Transthyretin Amyloidosis
Interventions
Patisiran, Vutrisiran
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
15
States / cities
La Mesa, California • Aurora, Colorado • Jacksonville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced Sep 5, 2026, 5:29 PM EDT
Recruiting Phase 1 Interventional

Testing for Safety and Colorectal Cancer Preventive Effects of ONC201

NCT05630794
View directory record Official record
Conditions
Colorectal Adenomatous Polyp, Colorectal Carcinoma, Familial Adenomatous Polyposis, Multiple Adenomatous Polyps
Interventions
Biopsy Procedure, Biospecimen Collection, Colonoscopy, Dordaviprone Hydrochloride, Questionnaire Administration, Sigmoidoscopy
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
5
States / cities
Ann Arbor, Michigan • St Louis, Missouri • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 5, 2026, 5:29 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Evuzamitide in PET/CT to Measure Potential Therapeutic Response in ATTR

NCT05635045
View directory record Official record
Conditions
Transthyretin Amyloidosis
Interventions
I 124-Evuzamitide
Drug
Lead sponsor
Columbia University
Other
Eligibility
50 Years to 105 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Sep 5, 2026, 5:29 PM EDT
Completed Phase 2 Interventional Results available

A Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients

NCT01187901
View directory record Official record
Conditions
Adenomatous Polyposis Coli
Interventions
Erlotinib, Sulindac, Placebo A, Placebo B
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 69 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 16, 2016 · Synced Sep 5, 2026, 5:29 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Early Detection of Neuropathy in ATTRv

NCT05311488
View directory record Official record
Conditions
Hereditary Amyloidosis, Transthyretin-Related
Interventions
neurofilament light chain, In-vivo Meissner Corpuscle imaging, Nerve conduction study
Diagnostic Test
Lead sponsor
University of Pennsylvania
Other
Eligibility
30 Years to 90 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Sep 5, 2026, 5:29 PM EDT
Recruiting Phase 2 Interventional

Using FAPI PET/MRI to Evaluate Prostate Cancer

NCT06675357
View directory record Official record
Conditions
Prostate Cancer Metastatic Disease, Prostate Cancers
Interventions
FAPI, Positron Emission Tomography (PET), Magnetic Resonance Imaging
Radiation · Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Sep 5, 2026, 5:29 PM EDT
Enrolling by invitation Phase 3 Interventional

A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

NCT06679946
View directory record Official record
Conditions
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Interventions
Vutrisiran
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
24
States / cities
Phoenix, Arizona • Beverly Hills, California • La Jolla, California + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Sep 5, 2026, 5:29 PM EDT
Completed No phase listed Observational

A Multicenter Observational Study to Evaluate the Effectiveness of Patisiran in Patients With Polyneuropathy of ATTRv Amyloidosis With a V122I or T60A Mutation

NCT04201418
View directory record Official record
Conditions
Hereditary Transthyretin-mediated (ATTRv) Amyloidosis, Polyneuropathy
Interventions
Patisiran
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
27
States / cities
Los Angeles, California • San Diego, California • Aurora, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2022 · Synced Sep 5, 2026, 5:29 PM EDT